Patterns of glucose lowering drugs utilization in Portugal and in the Netherlands. Trends over time

Primary Care Diabetes

Volumn 9, Issue 6, 2015, Pages 482-489

  Torre, Carla ^a,b   Guerreiro, José ^a   De Oliveira Martins, Sofia ^b   Raposo, João Filipe ^c,d   Martins, Ana Paula ^b   Leufkens, Hubert ^e  

^a CEFAR Centre for Health Evaluation and Research   (Portugal)

^b RESEARCH INSTITUTE FOR MEDICINES IMED ULISBOA   (Portugal)

^c UNIVERSIDADE NOVA DE LISBOA   (Portugal)

^d The Portuguese Diabetes Association (APDP)   (Portugal)

^e UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Diabetes mellitus, type 2; Hypoglycaemic drugs; Physician prescribing pattern; Portugal; Small area variation analysis; The Netherlands; Trends

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; METFORMIN; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA; VILDAGLIPTIN; BIOLOGICAL MARKER; GLUCOSE BLOOD LEVEL;

ARTICLE; DRUG COST; DRUG MARKETING; DRUG UTILIZATION; HUMAN; NETHERLANDS; PORTUGAL; PRESCRIPTION; PRIORITY JOURNAL; TIME; TREND STUDY; BLOOD; CLINICAL PRACTICE; CLINICAL TRIAL; COMPARATIVE STUDY; DIABETES MELLITUS; DRUG DATABASE; DRUG EFFECTS; DRUG UTILIZATION REVIEW; ECONOMICS; GLUCOSE BLOOD LEVEL; HEALTH CARE DISPARITY; METABOLISM; MULTICENTER STUDY; TIME FACTOR; TREATMENT OUTCOME; TRENDS;

BIOMARKERS; BLOOD GLUCOSE; DATABASES, PHARMACEUTICAL; DIABETES MELLITUS; DRUG COSTS; DRUG UTILIZATION REVIEW; HEALTHCARE DISPARITIES; HUMANS; HYPOGLYCEMIC AGENTS; NETHERLANDS; PORTUGAL; PRACTICE PATTERNS, PHYSICIANS'; TIME FACTORS; TREATMENT OUTCOME;

EID: 84949627739     PISSN: 17519918     EISSN: 18780210     Source Type: Journal    
DOI: 10.1016/j.pcd.2015.03.009     Document Type: Article

References (48)

1. G. Danaei, M.M. Finucane, Y. Lu, G.M. Singh, M.J. Cowan, C.J. Paciorek, and et al. National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participants Lancet 378 2011 31 40 10.1016/S0140-6736(11)60679-X
2. C.R. Chittleborough, J.F. Grant, P.J. Phillips, and A.W. Taylor The increasing prevalence of diabetes in South Australia: the relationship with population ageing and obesity Public Health 121 2007 92 99 10.1016/j.puhe.2006.09.017
3. T. Andersson, A. Ahlbom, C. Magnusson, and S. Carlsson Prevalence and incidence of diabetes in stockholm county 1990-2010 PLOS ONE 9 2014 e104033 10.1371/journal.pone.0104033
4. International Diabetes Federation IDF Diabetes Atlas 6th ed. 2013
5. L. Gardete-Correia, J.M. Boavida, J.F. Raposo, A.C. Mesquita, C. Fona, R. Carvalho, and et al. First diabetes prevalence study in Portugal: PREVADIAB study Diabet. Med. 27 2010 879 881 10.1111/j.1464-5491.2010.03017.x
6. Portuguese Society of Diabetology National Observatory of Diabetes Report - Diabetes - Facts and Numbers 2013 2013 (in Portuguese)
7. D.R. Whiting, L. Guariguata, C. Weil, and J. Shaw IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030 Diabetes Res. Clin. Pract. 94 2011 311 321 10.1016/j.diabres.2011.10.029
8. R.C. Turner, C.A. Cull, V. Frighi, and R.R. Holman Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group JAMA 281 1999 2005 2012
9. S.B. Souto, E.B. Souto, D.C. Braga, and J.L. Medina Prevention and current onset delay approaches of type 2 diabetes mellitus (T2DM) Eur. J. Clin. Pharmacol. 67 2011 653 661 10.1007/s00228-011-1038-z
10. S.E. Inzucchi, R.M. Bergenstal, J.B. Buse, M. Diamant, E. Ferrannini, M. Nauck, and et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetes Care 35 2012 1364 1379 10.2337/dc12-0413
11. N. Waugh, E. Cummins, P. Royle, C. Clar, M. Marien, B. Richter, and et al. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation Health Technol. Assess. 14 2010 1 248 10.3310/hta14360
12. Demography Report 2010: Older, More Numerous and Diverse Europeans: Commission Staff Working Document 2011 Publications Office of the European Union Luxembourg
13. M.J.P. van Avendonk, K.J. Gorter, M. van den Donk, and G.E.H.M. Rutten Insulin therapy in type 2 diabetes is no longer a secondary care activity in the Netherlands Prim. Care Diabetes 3 2009 23 28 10.1016/j.pcd.2008.10.007
14. Directorate-General of Health Guideline: Pharmacologic Treatment of Type 2 Diabetes Mellitus (Guideline No. 052/2011, Updated 10/12/2013) 2011 (In Portuguese)
15. G.E.H.M. Rutten, W. De Grauw, G. Nijpels, S. Houweling, F. Van de Laar, H. Bilo, and et al. NHG guideline on type 2 diabetes mellitus (third revision) Huisarts Wet. 56 2013 512 525
16. W. Schäfer, M. Kroneman, W. Boerma, M. van den Berg, G. Westert, W. Devillé, and et al. The Netherlands: health system review Health Syst. Trans. 12 2010 1 228 xxvii
17. R. Lub, P. Denig, P.B. van den Berg, K. Hoogenberg, and L.T.W. de Jong-van den Berg The impact of new insights and revised practice guidelines on prescribing drugs in the treatment of type 2 diabetes mellitus Br. J. Clin. Pharmacol. 62 2006 660 665 10.1111/j.1365-2125.2006.02711.x
18. P. Barros, S. Machado, and J. Simões Portugal. Health system review Health Syst. Trans. 13 2011 1 156
19. Portugal Memourandum of Understanding on Specific Economic Policy Conditionality (MoU) 2011
20. U. Bergman, P. Elmes, M. Halse, T. Halvorsen, H. Hood, P.K. Lunde, and et al. The measurement of drug consumption. Drugs for diabetes in Northern Ireland, Norway and Sweden Eur. J. Clin. Pharmacol. 8 1975 83 89
21. M.N. Dukes Introduction in Drug Utilization Studies: Methods and Uses. 1993 World Health Organization Regional Publications Geneva, Switzerland
22. Dutch Drug Information System (GIP), National Health Care Institute Dutch Drug Information System (GIP)/National Health Care Institute, 7-03-2014 (2014)
23. WHO Collaborating Centre for Drug Statistics Methodology Guidelines for ATC Classification and DDD Assignment 2013 2012 WHO Collaborating Centre for Drug Statistics Methodology Oslo, Norway
24. C.G. Vitry, and A.Z. Eeow International comparison of the utilization of antidiabetic medicines 28th Int. Conf. Pharmacoepidemiol. Ther. Risk Manag. Barcelona, 23-26 August 2012 Pharmacoepidemiol. Drug Saf. 21 Suppl. 3, pp. 163-164
25. R.A. DeFronzo Pharmacologic therapy for type 2 diabetes mellitus Ann. Intern. Med. 131 1999 281
26. W. Bennett, L. Wilson, S. Bolen, N. Maruthur, S. Singh, R. Chatterjee, and et al. Oral Diabetes Medications for Adults With Type 2 Diabetes: An Update, Comp. Eff. Rev. Number 27 2011 Johns Hopkins Univ. Evidence-Based Pract. Cent. under Contract to Agency Healthc. Res. Qual.
27. M.J.P. van Avendonk, and G.E.H.M. Rutten Insulin therapy in type 2 diabetes: what is the evidence? Diabetes Obes. Metab. 11 2009 415 432
28. Organization for Economic Co-Operation and Development Pharmaceutical consumption - health at a glance: Europe 2012 OCDE 2012 10.1787/9789264183896-38-en
29. N.R. Desai, W.H. Shrank, M.A. Fischer, J. Avorn, J.N. Liberman, S. Schneeweiss, and et al. Patterns of medication initiation in newly diagnosed diabetes mellitus: quality and cost implications Am. J. Med. 125 2012 302.e1 302.e7 10.1016/j.amjmed.2011.07.033
30. K.B. Filion, L. Joseph, J.-F. Boivin, S. Suissa, and J.M. Brophy Trends in the prescription of anti-diabetic medications in the United Kingdom: a population-based analysis Pharmacoepidemiol. Drug Saf. 18 2009 973 976 10.1002/pds.1802
31. S.E. Nissen, and K. Wolski Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality Arch. Intern. Med. 170 2010 1191 1201 10.1001/archinternmed.2010.207
32. S.E. Nissen, and K. Wolski Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes N. Engl. J. Med. 356 2007 2457 2471 10.1056/NEJMoa072761
33. European Medicines Agency European Medicines Agency Recommends Suspension of Avandia. Avandamet and Avaglim. EMA/585784/2010 2010
34. European Medicines Agency Update on ongoing European review of pioglitazone-containing medicines. Suspension of use of these medicines in France while Europe-wide review continues. EMA/278128/2011 2011
35. H.-G. Eichler, E. Abadie, A. Breckenridge, B. Flamion, L.L. Gustafsson, H. Leufkens, and et al. Bridging the efficacy-effectiveness gap: a regulator's perspective on addressing variability of drug response Nat. Rev. Drug Discov. 10 2011 495 506 10.1038/nrd3501
36. M. Gouveia, P. Laires, M. Borges, M. Augusto, and A.P. Martins Antidiabetic drugs and in-patient admissions attributable to diabetes in Portugal [In Portuguese] Acta Med. Portug. 25 2012 323 331
37. K.J.J. van Hateren, I. Drion, N. Kleefstra, K.H. Groenier, S.T. Houweling, K. van der Meer, and et al. A prospective observational study of quality of diabetes care in a shared care setting: trends and age differences (ZODIAC-19) BMJ Open 2 2012 10.1136/bmjopen-2012-001387
38. G. Sidorenkov, J. Voorham, D. de Zeeuw, F.M. Haaijer-Ruskamp, and P. Denig Treatment quality indicators predict short-term outcomes in patients with diabetes: a prospective cohort study using the GIANTT database BMJ Qual. Saf. 22 2013 339 347 10.1136/bmjqs-2012-001203
39. M. Gruesser, P. Hartmann, N. Schlottmann, and V. Joergens Structured treatment and teaching programme for type 2 diabetic patients on conventional insulin treatment: evaluation of reimbursement policy Patient Educ. Couns. 29 1996 123 130
40. K. Khunti, R. Gadsby, C. Millett, A. Majeed, and M. Davies Quality of diabetes care in the UK: comparison of published quality-of-care reports with results of the Quality and Outcomes Framework for Diabetes Diabet. Med. 24 2007 1436 1441 10.1111/j.1464-5491.2007.02276.x
41. A.A. Tahrani, M. McCarthy, J. Godson, S. Taylor, H. Slater, N. Capps, and et al. Diabetes care and the new GMS contract: the evidence for a whole county Br. J. Gen. Pract. 57 2007 483 485
42. P.W. Vermunt, I.E. Milder, F. Wielaard, C.A. Baan, J.D. Schelfhout, G.P. Westert, and et al. Behavior change in a lifestyle intervention for type 2 diabetes prevention in Dutch primary care: opportunities for intervention content BMC Fam. Pract. 14 2013 78 10.1186/1471-2296-14-78
43. P.W.A. Vermunt, I.E.J. Milder, F. Wielaard, J.H.M. de Vries, H.A.M. van Oers, and G.P. Westert Lifestyle counseling for type 2 diabetes risk reduction in Dutch primary care: results of the APHRODITE study after 0.5 and 1.5 years Diabetes Care 34 2011 1919 1925 10.2337/dc10-2293
44. C. Roumen, E. Corpeleijn, E.J.M. Feskens, M. Mensink, W.H.M. Saris, and E.E. Blaak Impact of 3-year lifestyle intervention on postprandial glucose metabolism: the SLIM study Diabet. Med. 25 2008 597 605 10.1111/j.1464-5491.2008.02417.x
45. B.R. Legido-Quigley, H. Panteli, D. Car, and J.M. McKee Clinical Guidelines for Chronic Conditions in the European Union 2013
46. A. Plat, F. Penning-van Beest, S. Kessabi, M. Groot, and R. Herings Change of initial oral antidiabetic therapy in type 2 diabetic patients Pharm. World Sci. 31 2009 622 626 10.1007/s11096-009-9321-0
47. S.E. Nissen The rise and fall of rosiglitazone Eur. Heart J. 31 2010 773 776 10.1093/eurheartj/ehq016
48. V. Lo Re, K. Haynes, E.E. Ming, J. Wood Ives, L.N. Horne, K. Fortier, and et al. Safety of saxagliptin: rationale for and design of a series of postmarketing observational studies Pharmacoepidemiol. Drug Saf. 21 2012 1202 1215 10.1002/pds.3318